← board
KRRO
Korro Bio, Inc.distress 4/10 · elevated risk$11.28-4%today-78% from 52w high
Lead: Alpha-1 Antitrypsin Deficiency
Revenue
pre-revenue
Liquidity
$157M
Runway
2.2 yrs
Shares 1y
+54%
Price & events
+7.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.6%
1D
-8.2%
1W
-17.8%
1M
-17.1%
3M
+5.1%
6M
-33.1%
1Y
-76.2%
2Y
-97.0%
5Y
-99.3%
All
Overview
- Market Cap
- $162.61M
- Volume
- 16.75K
- 52 Week Range
- $5.28 – $51.36
- Total Shares
- 14.42M
- Float Shares
- 9.53M
- Short %
- 13.27%
- % Held by Insiders
- 0.93%
- % Held by Institutions
- 96.88%
- RVOL
- 0.06x
- Beta
- 2.11
Pipeline stages · 1 programs
KRRO-110
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-10-31 | Phase 1/2 | KRRO-110 | Alpha-1 Anti-trypsin Deficiency, AATD | 42 | terminated |
Catalyst news & presentations · 7
- 2nd half of 2026Guided 40%regulatory submissionFiled (NDA/BLA)KRRO-121 · Regulatory submission to enable commencement of FIH trialSEC 8-K
- 2026Guided 40%enrollment completesecondaryPhase 1/2KRRO-110 · Study completion anticipated.SEC 8-K
- 2026Guided 40%readoutPhase 1/2KRRO-110 · Completion of Phase 1/2 study anticipated.SEC 8-K
- 2026-08-11earningsEarningsEarnings releaseyahoo
- second half of 2025readoutPhase 1/2KRRO-110 · Interim data readout expected.SEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 1/2KRRO-110 · First participant dosing anticipated.SEC 8-K
- November 4, 2024regulatory submissionFiled (NDA/BLA)KRRO-110 · Submitted Phase 1/2 clinical study to Australian Bellberry HREC.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $20 (+77% upside) · 10 analysts
- 2026-05-19HC Wainwright & Co.Buy
- 2026-05-18CitigroupBuy
- 2026-03-13Cantor FitzgeraldOverweight
- 2026-03-13Raymond JamesMarket Perform → Outperform
- 2026-02-19Clear StreetHold → Buy
- 2026-02-17William BlairMarket Perform → Outperform
Competitors — Alpha-1 Antitrypsin Deficiency
Recent news
- 2026-07-20Korro Bio, Inc. explores novel RNA editing approach for urea cycle disorder treatment - Traders Union
- 2026-07-17Form 4 Korro Bio Inc For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17Korro Bio, Inc. (KRRO) awards 7,500 RSUs to Chief Operating Officer - Stock Titan
- 2026-07-10Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
- 2026-07-08Price to sales forward of Korro Bio, Inc. – NASDAQ:KRRO - TradingView
- 2026-07-08Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
- 2026-07-07Korro Bio director Formela sells $1.54m in shares - Investing.com
- 2026-07-07Form 4 Korro Bio Inc For: 7 July By Investing.com - Investing.com Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.